Just reached your goal weight? Set a warning line a little above the weight you want to hold, weigh in once a week for 16 weeks, and see after each weigh-in whether you are on track, close to your line or above it.
Stopping your GLP-1? Choose "GLP-1 medication" when you start, and the chart also shows what the withdrawal trials measured after people stopped semaglutide or tirzepatide.
Free. Sign in with Google to save it. Last updated: 2026-09-27
Loading your plan…
Your stop date, stop weight, warning line and weekly weigh-ins are saved to your account, so the chart is there on any device. We only get your email and name from Google.
Already logging weigh-ins on your account page? They carry over to the plan.
One weigh-in per week is enough: same day, same scale, before breakfast. If you log more than one in a week, the latest counts.
Email alerts when you drift, a maintenance meal plan, and a printable report for your doctor. Coming soon.
No payment is taken and nothing is charged; this only tells us you want it.
Holding steady for a few months? See whether that can lower your life insurance rate, and what loose skin surgery costs, with or without insurance.
Two trials took people off a GLP-1 and kept weighing them. Both measured weight during the months after stopping, but neither publishes a number for week 16 itself, so the chart draws each trial's published average as a straight line from your stop weight. That is a simplification, and the tirzepatide numbers show why: most of the first year's regain came in its first half.
With S = your stop weight, L = your weight before the first dose minus S, and t = weeks since you stopped (0 to 16):
SURMOUNT-4 line: S × (1 + 0.099 × t / 28) STEP 1 extension line: S + (2/3) × L × t / 52
At week 16 that is S + 5.7% on the SURMOUNT-4 line and S + 20.5% of the weight you lost on the STEP 1 line. The shaded band is the space between the two lines. Without a starting weight there is no L, and only the SURMOUNT-4 line is drawn. Trial averages include people who regained almost nothing and people who regained more than they had lost; they describe groups, not you.
In the STEP 1 extension, people who stopped semaglutide had regained about two-thirds of the weight they lost within a year: 11.6 of 17.3 percentage points, ending 5.6% below where they began. In SURMOUNT-4, people switched from tirzepatide to placebo regained 14.0% of their body weight over 52 weeks, and 16.6% of them kept at least 80% of their loss.
Within months. In SURMOUNT-4 the placebo group was 9.9% heavier 28 weeks after switching and 14.8% heavier at 52 weeks (ClinicalTrials.gov results), so about two-thirds of the first year's regain had arrived by week 28. The STEP 1 extension weighed people several times in its off-treatment year but published a number only for the one-year point.
Pick a weight a little above the one you stopped at and treat crossing it as your signal: this plan offers your stop weight plus 3%, plus 5%, or a number you choose. A line closer to your stop weight flags drift sooner. What to do if you cross it, including anything about medication, is a conversation with your prescriber.
This plan shows your own weigh-ins against a line you chose and against published trial averages. It is information, not medical advice, and it never tells you to start, stop or change a medication or dose.
Embody · from $69/mowith one-year prepay ($828 upfront)
Check price →